About Tirzepatide: the Dual-Action Medicine Behind Mounjaro

What makes tirzepatide different from other weight-loss medicines

Most GLP-1 medicines on the UK market act on a single receptor. Tirzepatide targets two: the GLP-1 receptor and the GIP receptor, both of which are involved in regulating appetite, blood sugar and how quickly food leaves your stomach. Activating them together appears to produce a stronger effect on appetite suppression than either pathway alone.

The clinical trial programme behind tirzepatide's approval (SURMOUNT-1, which randomised over 2,500 adults with obesity) found average body-weight reductions of around 20–21% at the 15mg dose over 72 weeks. The SURMOUNT-1 paper in the New England Journal of Medicine sets out those figures in full. A later head-to-head trial, SURMOUNT-5, found tirzepatide produced greater average weight loss than semaglutide 2.4mg over the same period.

None of that means tirzepatide is right for everyone. Weight-loss medicine works best alongside changes to diet and activity. The clinical evidence is real, but so is the variation between individuals. A prescriber's job is to look at your full picture, not just the headline trial number. If you want a broader overview of how the medicine fits into the current UK treatment landscape, our page on Mounjaro covers that in detail.

Who the UK licence covers, and where NHS access currently sits

The private licence for tirzepatide covers adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. BMI thresholds are 2.5 kg/m² lower for South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds under UK guidance. Meeting the BMI threshold alone does not guarantee a prescription; the prescriber weighs the whole clinical picture.

On the NHS, access is more restricted. NICE's appraisal (TA1026, published in December 2024) recommended tirzepatide for adults with a BMI of 35 or above alongside at least one weight-related comorbidity, delivered through a structured programme with diet and activity support. NHS rollout is phased: from June 2025, the highest-need patients became eligible; a second cohort (BMI 35–39.9 with four or more qualifying conditions) became eligible from June 2026. Private treatment through a regulated pharmacy is an alternative for people who do not meet the current NHS criteria or who do not want to wait. There is more on how that route works on our treatment page.

Scotland, Wales and Northern Ireland operate separate access criteria. If your situation is country-specific, our prescribers can advise during your consultation.

Side effects: what the evidence actually says

The most commonly reported side effects in clinical trials were gastrointestinal: nausea, constipation, diarrhoea, indigestion and burping. For most people, these were at their worst in the first few weeks after starting or increasing the dose, then settled. That is precisely why treatment begins at 2.5mg, the starting dose exists to let your system adjust, not to produce significant weight loss in itself. Dose increases are made by the prescriber in steps, typically every four weeks.

Less common but more serious effects include acute pancreatitis. The MHRA flagged this in a Drug Safety Update in January 2026, and that development, alongside other recent regulatory updates, is covered in our news section: severe, persistent stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention. Gallbladder problems and, in people with diabetes, low blood sugar are also documented risks. Tirzepatide carries a Black Triangle (▼) marking, meaning it is subject to additional monitoring while longer-term post-marketing data accumulates.

If you are using oral contraceptives, the absorption of the pill may be reduced during the first four weeks of treatment and for four weeks after each dose increase; adding a non-oral method during those windows is the standard advice. You can read more clinical facts about Mounjaro including storage, injection sites and what to tell your GP, on a dedicated page. The NHS tirzepatide information page is also a reliable reference for side-effect detail written at patient level.

What to weigh up before starting a clinical conversation

Tirzepatide is not a cosmetic treatment. The MHRA is explicit that GLP-1 medicines are not assessed for quick or cosmetic weight loss. Clinicians who prescribe it appropriately are looking for a meaningful health benefit: reduced risk of cardiovascular disease, better blood-sugar control, improved mobility, relief from sleep apnoea. If your motivation is one of these, the clinical case is on solid ground.

Cost is part of the decision for most people. Eli Lilly raised the UK list price of Mounjaro significantly from September 2025; private market prices since then have typically ranged from roughly £149 to £375 per month depending on dose and provider. Our page on that price change explains what happened and what it means in practice. A transparent provider will always show you exactly what you are paying for, including consultation, prescription and delivery, with no subscription attached.

Before starting, your prescriber will want to know about any personal or family history of thyroid cancer, pancreatitis or inflammatory bowel disease, as well as any other medicines you take. There is no shortcut to that conversation, and there should not be. If you have read this far and think tirzepatide is worth discussing, our detailed Mounjaro guide is a good place to build your understanding before you speak to a prescriber. Our clinical team (introduced on our prescribers page) carries out every assessment personally. Consultations at nume are free, reviewed the same day by a GPhC-registered Independent Prescriber, and there is no obligation after you complete one.